Sign In
Not register? Register Now!
Pages:
5 pages/β‰ˆ1375 words
Sources:
5 Sources
Style:
APA
Subject:
Health, Medicine, Nursing
Type:
Coursework
Language:
English (U.S.)
Document:
MS Word
Date:
Total cost:
$ 29.16
Topic:

Therapy and Interventions for a Patient with Bipolar Disorder

Coursework Instructions:

Review this week’s Learning Resources, including the Medication Resources indicated for this week.
Reflect on the psychopharmacologic treatments you might recommend for the assessment and treatment of patients requiring bipolar therapy.
The Assignment: 5 pages
Examine Case Study: An Asian American Woman. Diagnosis-Bipolar Disorder. You will be asked to make three decisions concerning the medication to prescribe to this patient. Be sure to consider factors that might impact the patient’s pharmacokinetic and pharmacodynamic processes.
At each decision point, you should evaluate all options before selecting your decision and moving throughout the exercise. Before you make your decision, make sure that you have researched each option and that you evaluate the decision that you will select. Be sure to research each option using the primary literature.
Introduction to the case (1 page)
Briefly explain and summarize the case for this Assignment. Be sure to include the specific patient factors that may impact your decision making when prescribing medication for this patient.
Decision #1 (1 page)
Which decision did you select?
Why did you select this decision? Be specific and support your response with clinically relevant and patient-specific resources, including the primary literature.
Why did you not select the other two options provided in the exercise? Be specific and support your response with clinically relevant and patient-specific resources, including the primary literature.
What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources (including the primary literature).
Explain how ethical considerations may impact your treatment plan and communication with patients. Be specific and provide examples.
Decision #2 (1 page)
Why did you select this decision? Be specific and support your response with clinically relevant and patient-specific resources, including the primary literature.
Why did you not select the other two options provided in the exercise? Be specific and support your response with clinically relevant and patient-specific resources, including the primary literature.
What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources (including the primary literature).
Explain how ethical considerations may impact your treatment plan and communication with patients. Be specific and provide examples.
Decision #3 (1 page)
Why did you select this decision? Be specific and support your response with clinically relevant and patient-specific resources, including the primary literature.
Why did you not select the other two options provided in the exercise? Be specific and support your response with clinically relevant and patient-specific resources, including the primary literature.
What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources (including the primary literature).
Explain how ethical considerations may impact your treatment plan and communication with patients. Be specific and provide examples.
Conclusion (1 page)
Summarize your recommendations on the treatment options you selected for this patient. Be sure to justify your recommendations and support your response with clinically relevant and patient-specific resources, including the primary literature.
Note: Support your rationale with a minimum of five academic resources. While you may use the course text to support your rationale, it will not count toward the resource requirement. You should be utilizing the primary and secondary literature.
BACKGROUND INFORMATION
The client is a 26-year-old woman of Korean descent who presents to her first appointment following a 21-day hospitalization for onset of acute mania. She was diagnosed with bipolar I disorder.
Upon arrival in your office, she is quite “busy,” playing with things on your desk and shifting from side to side in her chair. She informs you that “they said I was bipolar, I don’t believe that, do you? I just like to talk, and dance, and sing. Did I tell you that I liked to cook?”
She weights 110 lbs. and is 5’ 5”
SUBJECTIVE
Patient reports “fantastic” mood. Reports that she sleeps about 5 hours/night to which she adds “I hate sleep, it’s no fun.”
You reviewed her hospital records and find that she has been medically worked up by a physician who reported her to be in overall good health. Lab studies were all within normal limits. You find that the patient had genetic testing in the hospital (specifically GeneSight testing) as none of the medications that they were treating her with seemed to work.
Genetic testing reveals that she is positive for CYP2D6*10 allele.
Patient did well enough on Lithium to be discharged from the hospital but admits she has not been taking it as prescribed. When further questioned on the subject, she provides no additional details.
MENTAL STATUS EXAM
The patient is alert, oriented to person, place, time, and event. She is dressed quite oddly- wearing what appears to be an evening gown to her appointment. Speech is rapid, pressured, tangential. Self-reported mood is euthymic. Affect broad. Patient denies visual or auditory hallucinations, no overt delusional or paranoid thought processes readily apparent. Judgment is grossly intact, but insight is clearly impaired. She is currently denying suicidal or homicidal ideation.
The Young Mania Rating Scale (YMRS) score is 22
RESOURCES
§ Chen, R., Wang, H., Shi, J., Shen, K., & Hu, P. (2015). Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems. European Journal of Clinical Pharmacology, 71(7), 835-841. doi:10.1007/s00228-015-1855-6
Decision Point One
Select what the PMHNP should do:
Begin Lithium 300 mg orally BID
Begin Risperdal 1 mg orally BID
Begin Seroquel XR 300 mg orally at HS

Coursework Sample Content Preview:

Therapy for Patients with Bipolar Disorder
Name
Department
Course
Instructor
Due Date
Therapy for Patients with Bipolar Disorder
Introduction 
The case study focuses on a 26-year-old woman of Korean descent who was hospitalized after acute mania and diagnosed with bipolar I disorder. Pharmacotherapy is an essential component for treating bipolar I disorder. However, trust in the interventions and compliance is necessary for the patient to be confident talking about the interventions and accepting the interventions. The Young Mania Rating Scale (YMRS) scored 22. Ideally, the client ought to be responsive to treatment with lithium and Depakote. Among bipolar lithium-treated patients, maintaining lithium dosage and therapeutic drug monitoring is also necessary to maintain health outcomes. The preferred interventions are taking lithium 300 mg orally, Depakote ER 500 mg orally at HS, and client education on dieting, weight loss, and drug/dose.
Decision #1 
In decision point one, the preferred choice is to begin Lithium 300 mg orally BID. Lithium was chosen as it is of the effective medications for controlling mania and stabilizing the mood. The results were unexpected as the client reported taking the drug on and off, indicating no adherence. The client’s response may likely be because of the medication’s side effects, such as nausea and diarrhea. Lithium remains a first-line treatment for bipolar, and it has acute antimanic efficacy and, where necessary, is combined with an atypical long-term treatment of bipolar disorders (Severus, Bauer & Geddes, 2018). Lithium can be in the form of immediate-release capsules (Eskalith or lithium carbonate), controlled-release tablets (Eskalith CR), and slow-release tablets (Lithobid) (Stovell, 2005).
 I chose not to begin Risperdal 1 mg orally BID and Seroquel XR 100 mg orally at HS. The client is of Korean descent and has the CYP2D6*10 allele, which is associated with the slowing down of Risperdal (risperidone) (Chen et al., 2015). There is a higher risk of sedative and lethargic side effects when treating the client with Risperdal because of the slow clearance. Risperdal is FDA approved for acute mania/mixed mania and adjunct to lithium (Stahl, 2024). The medication is dosed twice a day, but there can also be compliance issues, and weight gain is not as much as Zyprexa.
Seroquel (quetiapine), the mood stabilizer, and dopamine, multimodal serotonin antidepressant is FDA approved for acute mania in adults. However, some side effects are weight gain, constipation, and dry mouth, and the client does not like this (Laureate Education, 2016). While there is weight gain and different related conditions for other medications to treat bipolar, many people are still treated with lithium, an effective mood stabilizer (Gomes-da-Costa et al., 2021). 
 I expected there would be an improvement in symptoms reduction, but this was not the case as the client was reluctant to take the medication consistently. Lithium has been used to prevent the recurrence of mania and depressive symptoms making the medication one of the most preferred for long-term treatment of mania (Alda, 2015). Lithium has also been found effective for the maintenance tre...
Updated on
Get the Whole Paper!
Not exactly what you need?
Do you need a custom essay? Order right now:

πŸ‘€ Other Visitors are Viewing These APA Coursework Samples:

HIRE A WRITER FROM $11.95 / PAGE
ORDER WITH 15% DISCOUNT!